Evaluating UNITED THERAPEUTICS CORP (NASDAQ:UTHR) using Peter Lynch’s legendary strategy

With a strategy that emphasized steady earnings growth and a strong market position, Peter Lynch sought out long-term winners. We put UNITED THERAPEUTICS CORP (NASDAQ:UTHR) to the test against his stock-picking rules.

Why Peter Lynch may take an interest in UNITED THERAPEUTICS CORP (NASDAQ:UTHR)

• With a favorable Return on Equity (ROE) of 18.55%, UTHR demonstrates its ability to deliver attractive returns for shareholders. This metric highlights the company's effective management of assets and its profitability.
• A Debt/Equity ratio of 0.0 highlights UTHR's commitment to maintaining financial stability.
• Over the past 5 years, UTHR has demonstrated 16.88 growth in EPS, signifying its positive financial trajectory and potential for future profitability.
• With a PEG ratio of 0.74, UTHR is valued very reasonably for the growth it experiences.
• A Current Ratio of 5.25 suggests that UTHR has sufficient assets to cover its short-term liabilities.

Fundamental analysis of UTHR

As part of its analysis, ChartMill provides a comprehensive Fundamental Rating for each stock. This rating, ranging from 0 to 10, is updated on a daily basis and is based on the evaluation of various fundamental indicators and properties.

UTHR gets a fundamental rating of 7 out of 10. The analysis compared the fundamentals against 570 industry peers in the Biotechnology industry. UTHR gets an excellent profitability rating and is at the same time showing great financial health properties. UTHR is valued quite cheap, while showing a decent growth score. This is a good combination! This makes UTHR very considerable for value and quality investing!

For an up to date full fundamental analysis you can check the fundamental report of UTHR

More Affordable Growth stocks can be found in our Peter Lynch screener.

Disclaimer

This is not investing advice! The article highlights some of the observations at the time of writing, but you should always make your own analysis and invest based on your own insights.